Pharmacosmos announces the establishment of the specialty pharmaceutical company Pharmacosmos Therapeutics, Inc. in the US, dedicated to the commercialisation of intravenous iron for the treatment of iron deficiency anaemia (IDA).
Lars Christensen, MD, President and CEO of Pharmacosmos A/S said “I am proud to announce the establishment of Pharmacosmos Therapeutics, Inc. in the US. Built upon the heritage of the global Pharmacosmos Group and its expertise in bringing innovative treatments to patients suffering from iron deficiency anaemia around the world, Pharmacosmos Therapeutics, Inc. will have the benefit of a singular focus with all efforts directed toward covering unmet clinical needs for these patients in the US.”
“Pharmacosmos Therapeutics, Inc. will expand the ongoing commitment of Pharmacosmos Group to change the way iron deficiency anaemia is treated. Pharmacosmos Therapeutics’ vision is to grow into a complete stand-alone specialty pharmaceutical company that can bring a new treatment option to patients in the fast growing intravenous iron market and, in time, become a leading player in the treatment of iron deficiency anaemia in the United States.” said Michael Ryde, CEO of Pharmacosmos Therapeutics, Inc.
Initial members of the leadership team of Pharmacosmos Therapeutics Inc. include
Pharmacosmos Therapeutics Inc. is based in Morristown, New Jersey.
For more information, please contact
Robert Guglielmetti, Executive Vice President, Chief Financial Officer
Tel: +45 59 48 59 59
For media inquiries:
Fonnesbech & Estrup
Tel: +45 28 74 87 10
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA and recently also in China, and through partners, Pharmacosmos markets its products across the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?